The factor XIII‐A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations
- 27 January 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 18 (4), 885-894
- https://doi.org/10.1111/jth.14744
Abstract
No abstract availableFunding Information
- National Heart, Lung, and Blood Institute (F31HL139100, R01HL126974, R56HL094740, T32HL69768)
This publication has 49 references indexed in Scilit:
- The antifibrinolytic function of factor XIII is exclusively expressed through α2-antiplasmin cross-linkingBlood, 2011
- Factor XIII: novel structural and functional aspectsJournal of Thrombosis and Haemostasis, 2011
- Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogramThrombosis and Haemostasis, 2009
- Factor XIII Val34Leu variant protects against coronary artery diseaseThrombosis and Haemostasis, 2007
- Factor XIII Val34Leu Variant Is Protective against Venous Thromboembolism: A HuGE Review and Meta-AnalysisAmerican Journal of Epidemiology, 2006
- The protective effect of the factor XIII Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen levelJournal of Thrombosis and Haemostasis, 2005
- Fibrinogen gamma-chain splice variant γ′ alters fibrin formation and structureBlood, 2003
- Examining Thrombin Hydrolysis of the Factor XIII Activation Peptide Segment Leads to a Proposal for Explaining the Cardioprotective Effects Observed with the Factor XIII V34L MutationOnline Journal of Public Health Informatics, 2000
- Cross-linking of α2-antiplasmin to fibrin is a key factor in regulating blood clot lysisBlood Coagulation & Fibrinolysis, 1993
- Gerinnungsphysiologische Schnellmethode zur Bestimmung des FibrinogensActa Haematologica, 1957